Published: 16 April 2024
Author(s): Ailin Li, Wengen Zhu, Xin Liu
Issue: May 2024
Section: Letter to the Editor

Cerebral venous thrombosis (CVT) is a rare clotting disorder that mainly affects younger females. In order to achieve recanalization of cerebral veins and reduce the risk of venous thromboembolism (VTE), current guidelines recommend anticoagulation therapy for a period of 3 to 12 months for patients with CVT [1,2]. This therapy usually involves the use of vitamin K antagonists (VKAs) or low-molecular-weight heparin (LMWH). However, recent studies have shown that direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban have several advantages over VKAs in specific population groups requiring thrombosis prophylaxis [3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.